Inhibition of PD-L1 via atezolizumab in combination with bevacizumab, an anti-angiogenic agent that targets VEGF, showed a favorable effect on overall survival and prolonged the free-of cancer period compared to sorafenib as monotherapy [111]. Here, VEGFA is linked to cancer.